Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma Maria I. Toki, MD,

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing Klazien Matter-Walstra, PhD, Matthias.

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases Jong-Mu Sun, MD, Wei.

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival Junna Oba, MD, PhD, Takeshi Nakahara,

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer Patrick Wald,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Asishana A. Osho, MD, MPH, Christopher J

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Anya M. Litvak, MD, Paul K. Paik, MD, Kaitlin M. Woo, MS, Camelia S

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small- Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of.

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial Kenneth S. Thress, PhD, Vivien.

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases Hironori Uruga, MD, PhD, Emine Bozkurtlar,

Stromal Macrophage Expressing CD204 is Associated with Tumor Aggressiveness in Lung Adenocarcinoma Yoichi Ohtaki, MD, Genichiro Ishii, MD, PhD, Kanji.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Clinical Relevance of Our Multimodality Prognostic Score

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective.

It’s All in the “Swerve of the Curve”

Genetic Changes in Squamous Cell Lung Cancer: A Review

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Journal of Thoracic Oncology

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment Tiffany G. Huynh, BA, Vicente Morales-Oyarvide, MD, MPH, Meghan J. Campo, MD, Justin F. Gainor, MD, Emine Bozkurtlar, MD, Hironori Uruga, MD, PhD, Ling Zhao, MD, Maria Gomez-Caraballo, BA, Aaron N. Hata, MD, PhD, Eugene J. Mark, MD, Michael Lanuti, MD, Jeffrey A. Engelman, MD, PhD, Mari Mino-Kenudson, MD Journal of Thoracic Oncology Volume 11, Issue 11, Pages 1869-1878 (November 2016) DOI: 10.1016/j.jtho.2016.08.134 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Representative images of programmed cell death ligand 1 (PD-L1) and CD8 immunostaining in lung adenocarcinomas (magnification, ×200). A-C show membranous staining of PD-L1 on no (<1%), 20% (≥5% to <50%), and 100% (≥50%) of tumor cells, respectively. D and G show PD-L1 expression in <1% and 20% (≥10%) of stromal immune cells, respectively. Cytoplasmic expression of CD8 in tumor infiltrating T cells is graded as 0, 1 (E), 2 (H), and 3, and is subsequently dichotomized into negative (0–1) and positive (2–3). CD8+ stomal cells are assessed based on the percentage of positive lymphocytes compared with the total number of nucleated cells in the stromal compartments and are dichotomized into negative (≤10% of stromal nuclei, F) and positive (>10% of stromal nuclei, I). Journal of Thoracic Oncology 2016 11, 1869-1878DOI: (10.1016/j.jtho.2016.08.134) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Programmed cell death ligand 1 H score stratified by molecular alterations. H scores of KRAS mutants, those with other molecular alterations and SNaPshot wild-type cases (None) are significantly higher than those of EGFR and ALK mutants (p < 0.0001, p < 0.01, and p < 0.001 for both, respectively). Journal of Thoracic Oncology 2016 11, 1869-1878DOI: (10.1016/j.jtho.2016.08.134) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Kaplan-Meier curves showing progression-free survival (PFS) and overall survival (OS) of lung adenocarcinoma patients with positive and negative programmed cell death ligand 1 (PD-L1; expression for 5% cutoff). (A) Patients who have PD-L1 expression on ≥5% of tumor cells had a lower 5-year PFS rate than those without (66% versus 75%, log-rank p = 0.007). The median PFS for both groups was undefined. (B) Similarly, patients with positive PD-L1 expression had a lower 5-year OS rate than those with negative PD-L1 expression (72% vs. 85%, log-rank p = 0.011). The median OS for both groups was undefined. Journal of Thoracic Oncology 2016 11, 1869-1878DOI: (10.1016/j.jtho.2016.08.134) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1 Journal of Thoracic Oncology 2016 11, 1869-1878DOI: (10.1016/j.jtho.2016.08.134) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2 Journal of Thoracic Oncology 2016 11, 1869-1878DOI: (10.1016/j.jtho.2016.08.134) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions